Source link : https://www.newshealth.biz/health-news/promising-results-for-drug-for-depression-plus-insomnia/
Seltorexant, an investigational drug being developed by Johnson & Johnson, met all primary and secondary endpoints in a phase 3 trial of patients with major depressive disorder (MDD) with insomnia symptoms, the company has announced. Seltorexant is an investigational potential first-in-class selective antagonist of the human orexin 2 receptor being studied for the adjunctive treatment […]
Author : News Health
Publish date : 2024-05-30 09:04:42
Copyright for syndicated content belongs to the linked Source.
Categories